麻豆视频

Desk Research

Desk research starts by mapping the addressable breast cancer screening pathway and the typical places where spending is recorded, then aligning that to North America level coverage. Public sources are used to anchor the demand pool and screening activity, including CDC screening guidance and utilization summaries, National Cancer Institute materials and SEER cancer statistics, FDA device and test-related public databases, and CMS reimbursement and coding references where applicable.

To reduce guesswork, we also read non-paywalled clinical guidelines and peer-reviewed journals that discuss screening intervals, modality mix, and adoption shifts (for example, the move toward 3D mammography in some settings). On the supply side, we review company filings, investor presentations, and credible press to understand portfolio focus and geographic exposure. For select cross-checks, we use paid subscriptions for company financials and patent databases, and we may also reference an import-export shipment-level database when equipment flows help explain modality availability. The sources listed here are illustrative, and many other public documents and references were reviewed to collect data, validate assumptions, and clarify open questions.

Primary Interviews and Surveys

Primary work is used to pressure test the desk view on what is actually ordered, reimbursed, and performed, then to confirm practical splits by test category and care setting. Interviews cover test providers, imaging administrators, lab stakeholders, clinicians, and distribution participants across the United States, Canada, and Mexico, so the model reflects real screening cadence and the pricing behavior observed in those markets.

Distribution of primary research fieldwork respondents

Market sizing is built using a top-down approach where the screening eligible population, screening rate, and modality mix are combined to reconstruct annual test volumes, then converted to value using typical reimbursed price points and observed pricing ranges. Where inputs vary by country, the United States, Canada, and Mexico are sized separately and aggregated to the North America total at the end.

To keep totals realistic, we corroborate results with selective bottom-up approximations, including sampled pricing by modality, channel checks on testing volumes, and supplier-level directional roll-ups that help correct overstatements. Key inputs in the model include screening participation by age band, frequency assumptions by guideline and real practice, the share of imaging versus genomic screening, movement toward tomosynthesis and other imaging tests, and policy or reimbursement signals that change utilization. For forecasting, scenario analysis is used so the base case growth reflects expert consensus on capacity expansion, awareness programs, and technology adoption, with upper and lower cases used to understand sensitivity. When bottom-up signals are incomplete, gaps are handled by applying conservative ranges, then rechecking the implied per capita screening activity for each country.

Validation is done through multiple checks so totals match independent signals, and any unusual jumps are challenged before numbers are finalized. We compare implied screening volumes and value per test against public utilization references, reimbursement benchmarks, and the interviewed ranges, then document and resolve variances through follow-up.

Before sign-off, the model and assumptions go through a step-by-step analyst review where formulas, unit consistency, and currency timing are rechecked. Reports are refreshed annually, and interim updates are triggered when a material event occurs, such as a guideline change, reimbursement shift, or a major regulatory action affecting screening. Right before delivery, the full dataset is reviewed again so the latest updated view is reflected in the final output.

Published market sizes for breast cancer screening tests in North America can look different even when the topic is described similarly, because the counted services and year-to-year pricing logic are not always aligned. Differences also come from how each publisher treats follow-on diagnostic testing, how local pricing is converted into USD, and how recently assumptions were refreshed.

Some external estimates are broader and include breast cancer diagnostics categories like biopsy and blood tests in the same revenue pool. In 麻豆视频, the number is limited to screening tests only (genomic and imaging screening), and it is built by linking screening activity and modality mix to realistic price points that were validated through interviews and cross-checks.

Benchmark comparison

The table shows that most gaps are explained by what gets counted as screening versus downstream diagnostics, followed by how screening uptake and price per test are treated in the base year. By tying the value build-up to observable screening activity and checked pricing ranges, we can keep the estimate transparent and repeatable even when external scopes are not aligned.